Review of the scheme to control the cost of branded health service medicines : consultation response

Department of Health and Social Care - Having considered the consultation responses and wider engagement with key stakeholders, the UK government has decided to: continue to operate the statutory scheme in a way that is broadly commercially equivalent to the voluntary scheme; set amended payment percentages for 2024 to 2026 based on an allowed growth rate that has been increased to 2%; implement an exemption from payment for medicines containing a new active substance; and include exemptions from payment for exceptional central procurements and centrally procured vaccines.Consultation responseMore detail
Source: The Kings Fund - Health Management Specialist Collection - Category: Health Management Authors: Tags: NHS finance Source Type: news